The short answer
Two trials found weight reduction alongside improved blood sugar. They studied adults with type 2 diabetes, using different comparisons and treatment periods.
Against placebo
In a 320-person trial, participants received weekly mazdutide or placebo for 24 weeks. Average weight changes were:
Mazdutide 4 mg: 5.61% loss.
Mazdutide 6 mg: 7.81% loss.
Placebo: 1.26% loss.
Blood sugar was the primary outcome. Diarrhoea, reduced appetite and nausea were common adverse events.
Loss by group in placebo-controlled trial; differences versus dulaglutide
24 weeks: mazdutide 4 mg / 6 mg / placebo
5.61% / 7.81% / 1.26% loss
28 weeks: mazdutide 4 mg / 6 mg versus dulaglutide
3.78 / 5.76 percentage points more loss
Original visual based on the studies cited below.
| Group or measure | Result |
|---|---|
| 24 weeks: mazdutide 4 mg / 6 mg / placebo | 5.61% / 7.81% / 1.26% loss |
| 28 weeks: mazdutide 4 mg / 6 mg versus dulaglutide | 3.78 / 5.76 percentage points more loss |
Against dulaglutide
A separate 731-person trial compared mazdutide with dulaglutide 1.5 mg over 28 weeks, alongside oral diabetes medicines.
Weight reduction was 3.78 percentage points greater with mazdutide 4 mg and 5.76 points greater with 6 mg. These are differences between treatments, not total weight loss. Digestive adverse events were more common with mazdutide.
The useful takeaway
These studies add evidence for people with diabetes. They do not compare mazdutide with obesity-dose semaglutide or tirzepatide, and they cannot establish which medicine is best for an individual.